BNP Paribas Arbitrage SNC Sells 33,345 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

BNP Paribas Arbitrage SNC lessened its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Get Rating) by 38.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 53,794 shares of the company’s stock after selling 33,345 shares during the period. BNP Paribas Arbitrage SNC’s holdings in IDEXX Laboratories were worth $17,526,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Van ECK Associates Corp raised its stake in IDEXX Laboratories by 6.1% during the third quarter. Van ECK Associates Corp now owns 12,723 shares of the company’s stock worth $4,145,000 after buying an additional 737 shares during the last quarter. Amalgamated Bank increased its stake in IDEXX Laboratories by 1.1% in the third quarter. Amalgamated Bank now owns 22,426 shares of the company’s stock valued at $7,306,000 after purchasing an additional 251 shares in the last quarter. Mutual of America Capital Management LLC increased its stake in IDEXX Laboratories by 0.6% in the third quarter. Mutual of America Capital Management LLC now owns 12,379 shares of the company’s stock valued at $4,033,000 after purchasing an additional 73 shares in the last quarter. Mitsubishi UFJ Trust & Banking Corp increased its stake in IDEXX Laboratories by 17.2% in the third quarter. Mitsubishi UFJ Trust & Banking Corp now owns 63,139 shares of the company’s stock valued at $20,571,000 after purchasing an additional 9,283 shares in the last quarter. Finally, Bank of Montreal Can increased its position in shares of IDEXX Laboratories by 12.2% during the second quarter. Bank of Montreal Can now owns 106,269 shares of the company’s stock worth $38,326,000 after acquiring an additional 11,518 shares in the last quarter. Institutional investors own 87.90% of the company’s stock.

Insider Activity

In other news, SVP Kathy V. Turner sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 14th. The shares were sold at an average price of $504.59, for a total value of $1,009,180.00. Following the sale, the senior vice president now owns 7,380 shares of the company’s stock, valued at $3,723,874.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, SVP Kathy V. Turner sold 1,000 shares of the company’s stock in a transaction that occurred on Thursday, February 9th. The shares were sold at an average price of $505.04, for a total transaction of $505,040.00. Following the sale, the senior vice president now owns 6,941 shares of the company’s stock, valued at approximately $3,505,482.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Kathy V. Turner sold 2,000 shares of the stock in a transaction on Tuesday, February 14th. The stock was sold at an average price of $504.59, for a total transaction of $1,009,180.00. Following the completion of the transaction, the senior vice president now directly owns 7,380 shares in the company, valued at approximately $3,723,874.20. The disclosure for this sale can be found here. Insiders own 2.06% of the company’s stock.

Wall Street Analysts Forecast Growth

IDXX has been the subject of several recent research reports. Atlantic Securities boosted their target price on shares of IDEXX Laboratories from $470.00 to $600.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 7th. JPMorgan Chase & Co. boosted their target price on shares of IDEXX Laboratories from $525.00 to $550.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 7th. Barclays boosted their target price on shares of IDEXX Laboratories from $582.00 to $590.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 8th. TheStreet raised shares of IDEXX Laboratories from a “c+” rating to a “b-” rating in a research report on Friday, November 25th. Finally, Morgan Stanley decreased their target price on shares of IDEXX Laboratories from $573.00 to $543.00 and set an “overweight” rating for the company in a research report on Tuesday, November 15th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and an average target price of $514.75.

IDEXX Laboratories Stock Up 2.3 %

IDEXX Laboratories stock opened at $471.42 on Wednesday. The company has a debt-to-equity ratio of 1.14, a quick ratio of 0.59 and a current ratio of 0.89. The stock has a market cap of $39.08 billion, a PE ratio of 58.71, a price-to-earnings-growth ratio of 2.64 and a beta of 1.18. IDEXX Laboratories, Inc. has a fifty-two week low of $317.06 and a fifty-two week high of $560.92. The firm’s 50-day simple moving average is $479.06 and its 200 day simple moving average is $413.11.

IDEXX Laboratories (NASDAQ:IDXX – Get Rating) last released its earnings results on Monday, February 6th. The company reported $2.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.92 by $0.13. The firm had revenue of $828.60 million for the quarter, compared to analysts’ expectations of $820.91 million. IDEXX Laboratories had a net margin of 20.17% and a return on equity of 124.51%. The company’s quarterly revenue was up 3.4% on a year-over-year basis. During the same period in the previous year, the company earned $1.89 earnings per share. Research analysts predict that IDEXX Laboratories, Inc. will post 9.58 EPS for the current fiscal year.

IDEXX Laboratories Profile

(Get Rating)

IDEXX Laboratories, Inc engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water, Livestock, Poultry and Dairy (LPD), and Other.